24-Hour Turnaround

Quick Screen
in 24 Hours

Submit your device details and receive a data-driven risk assessment benchmarked against 800+ outcome-labeled biomedical companies in our proprietary cohort substrate, growing with every engagement. Results delivered in 24 hours.

See All Tiers
$5,000 Flat Fee
24h Turnaround
800+ Outcome-labeled Companies in Cohort Substrate
2–3 Page Report

Your Assessment Path

Scalable Risk Assessment

START HERE

Quick Screen

$5,000
24-hour turnaround

Rapid automated assessment across 4 strategic domains: clinical viability, regulatory pathway, commercialization risk, and manufacturing scalability.

  • ✓2–3 page data-driven report
  • ✓Benchmarked against 800+ outcome-labeled companies in cohort substrate
  • ✓Risk scoring with confidence levels
Get Quick Screen

Vantage Index

$7,500–$25,000
48-hour turnaround

Full 20-category analysis with your role-specific framing: founder readiness, investor committee summaries, M&A integration risk, or licensing potential.

  • ✓5–12 page tailored report
  • ✓Competitive benchmarking analysis
  • ✓30–60 min physician debrief
  • ✓Actionable recommendations
Explore the Vantage Index

Quick Screen fee applies toward upgrade

Start with Quick Screen to validate fit, then graduate to a role-specific Vantage Index for deeper insights. Most customers use Quick Screen to baseline risk, then upgrade within 48 hours for full analysis. Your initial assessment cost is credited toward any upgrade.

See Where You Stand

Quick Screen

Tell us about your device. We'll analyze and score it in 24 hours.

Quick Screen

$5,000
24-hour turnaround with automated data-driven analysis

Analyzed by a Physician & Biomedical Engineer Team

Your device is assessed using our proprietary multi-factor scoring framework built from 800+ outcome-labeled biomedical companies in our cohort substrate, growing with every engagement. Led by Arvind Ravinutala, MD and Aswini Ravinutala, BME.

See a Sample Evaluation

What You Receive in 24 Hours

📊

Composite Risk Score

Single composite score across multiple assessment domains

⚠️

Top 3 Risk Flags

Critical risks that need attention

✅

Top 3 Strengths

Defensible advantages for strategy

🎯

Go / No-Go

Clear recommendation with confidence

Company and device name are required
Valid email is required
100-200 words helps our analysis engine provide better context

By submitting, you agree to our Privacy Policy and Terms of Service

Need deeper analysis?

Upgrade any Quick Screen to a full Vantage Index ($7,500) for domain-by-domain breakdowns, competitive positioning, and physician-engineer co-review with written commentary.

Compare tiers
⚙️

Analyzing Your Device

Running your device through our proprietary multi-domain assessment...

1

Data Collection

Aggregating relevant data across proprietary sources...

2

Clinical Analysis

Physician-led review of clinical risk factors...

3

Technical Assessment

Engineering feasibility and risk evaluation...

4

Commercial Viability

Market and reimbursement landscape analysis...

5

Risk Calibration

Benchmarking against 800+ outcome-labeled biomedical companies in our proprietary cohort substrate...

6

Score Generation

Computing your Vantage Index...

✓

Your Quick Screen is Ready

Your Vantage Index has been generated and is being prepared for delivery.

Report sent to:

you@company.com

Check your inbox (and spam folder) for your report

Turnaround time:

Instant Results

Your Quick Screen appears in the report

The 7-Level Vantage Index Scale

0–14: Critical Significant risk
15–29: Concerning Notable challenges
30–44: Adequate Acceptable position
45–59: Moderate Balanced risk-reward
60–74: Favorable Competitive strength
75–89: Strong Excellent positioning
90–100: Exceptional Market leader potential

Want More Insight?

Your Quick Screen gives you a data-driven baseline in 24 hours. Upgrade to Founder Report ($7,500) for:

  • Full multi-domain breakdown across all risk dimensions
  • Expert analyst review and validation
  • Top 3 strengths + Top 3 risks with evidence
  • Percentile benchmarking vs 800+ outcome-labeled companies in cohort substrate
  • Remediation priorities and next steps
  • 48-hour turnaround with data citations
Upgrade to a full Diligence Report Back to Pricing